Pluristem Therapeutics, Inc. (PSTI) News
Filter PSTI News Items
PSTI News Results
|Loading, please wait...|
Latest PSTI News From Around the Web
Below are the latest news stories about Pluristem Therapeutics Inc that investors may wish to consider to help them evaluate PSTI as an investment opportunity.
In this article, we discuss the 15 worst stock picks of Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to the 5 Worst Stock Picks of Cathie Wood. Cathie Wood, the chief ARK Investment Management, is often hailed as the champion of “disruptive innovation” at the stock market. […]
I hope you enjoyed the long weekend, but it's time to get back into investing with the biggest pre-market stock movers for Tuesday!
Mainz Biomed (MYNZ) +14%. Vinco Ventures (BBIG) +13%. Digital World Acquisition (DWACW) +11%. Pluristem Therapeutics (PSTI) +10%
Welcome back, trader!
Pluristem Therapeutics (PSTI) and Tnuva Group, Israel’s largest food producer, announce the launch of an innovative collaboration to develop, manufacture and commercialize…
Pluristem Therapeutics Inc (NASDAQ: PSTI ) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products. The collaboration started with the incorporation of a new company (NewCo) that will receive exclusive, global, royalty-bearing licensing rights to use Pluristem''s Full story available on Benzinga.com
Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?
NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
Yaky Yanay, CEO and President, Pluristem Yaky Yanay, CEO and President, Pluristem Zami Aberman, Chairman, Pluristem Zami Aberman, Chairman, Pluristem Haim Gavrieli, Chairman, Tnuva Group Haim Gavrieli, Chairman, Tnuva Group Eyal Malis, CEO, Tnuva Group Eyal Malis, CEO, Tnuva Group Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power multipliers in consumer-packaged goods, research and development (R&D), c
Dawson James analyst Jason Kolbert maintained a Buy rating on Pluristem (PSTI – Research Report) on December 1 and set a price target of $9.00. The company's shares closed last Tuesday at $1.53. According to TipRanks.com, Kolbert 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $9.00 average price target.
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.